Given that previous reports indicated that A3A was preferentially expressed in CD14-positive monocytes [42]–[44], we tried to determine whether the pool of A3A molecules present in target cells could inhibit de novo infection of myeloid cells by HIV-1. Here, APOBEC3A is linked to infection.